Merck KGaA logo

Merck KGaA (MRK)

Market Closed
12 Jun, 15:30
XETRA XETRA
133. 25
-2.15
-1.5879%
- Market Cap
23.04 P/E Ratio
2.39% Div Yield
423,077 Volume
0 Eps
135.4
Previous Close
Add Transaction
Day Range
133.25 137.25
Year Range
100.7 140.25
Want to track MRK and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

MRK closed today lower at €133.25, a decrease of -1.5879% from yesterday's close, completing a monthly increase of 21.4123% or €23.5. Over the past 12 months, MRK stock gained 7.8074%.
MRK pays dividends to its shareholders, with the most recent payment made on Apr 29, 2026. The next estimated payment will be in 1 month ago on Apr 29, 2026 for a total of €2.2.
The last earnings report, released on May 13, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0.02%, based on the last three reports.
Merck KGaA has completed 2 stock splits, with the recent split occurring on Jun 30, 2014.
The company's stock is traded on 10 different exchanges and in various currencies, with the primary listing on XETRA (EUR).

MRK Chart

Merck KGaA (MRK) FAQ

What is the stock price today?

The current price is €133.25.

On which exchange is it traded?

Merck KGaA is listed on XETRA.

What is its stock symbol?

The ticker symbol is MRK.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 2.39%.

What is its market cap?

As of today, no market cap data is available.

Has Merck KGaA ever had a stock split?

Merck KGaA had 2 splits and the recent split was on Jun 30, 2014.

Merck KGaA Profile

Specialty Retail Industry
Consumer Discretionary Sector
Belen Garijo Lopez CEO
XETRA Exchange
DE0006599905 ISIN
DE Country
59,020 Employees
27 Apr 2026 Last Dividend
24 Jan 2007 Last Split
- IPO Date

Overview

Merck KGaA is a prominent science and technology entity based in Germany, spanning its operations through diversified sectors such as Life Science, Healthcare, and Electronics. As of its inception in 1668, the company has distinguished itself by contributing significantly to academic, biotech, pharmaceutical, and industrial fields with its comprehensive range of tools, chemicals, and technology solutions. It is an influential subsidiary of E. Merck KGaA, with its headquarters located in Darmstadt, Germany. Through its international collaborations and in-licensing agreements with companies like Debiopharm International SA, Jiangsu Hengrui Pharmaceuticals Co. Ltd., and Abbisko Therapeutics Co. Ltd., Merck KGaA continues to bolster its position in developing innovative treatments in areas such as oncology, neurology, and various other critical disease sectors.

Products and Services

  • Life Science Solutions

    Merck KGaA offers an extensive suite of products tailored for the Life Science industry, catering to academic labs, biotech, and pharmaceutical manufacturers. This includes process development expertise, technologies for continuous bioprocessing, testing kits, chemical reagents, and services designed for air, water, and soil analysis. They also provide tools that assess the nutritional value and identify quality inconsistencies, aiming to support the entire biopharmaceutical manufacturing value chain.

  • Healthcare and Biopharmaceuticals

    The company plays a pivotal role in the healthcare sector by discovering, developing, manufacturing, and marketing a broad portfolio of prescription drugs and biopharmaceutical products. These offerings are directed toward treating conditions in oncology, neurology and immunology, fertility, endocrinology, cardiovascular diseases, diabetes, thyroid disorders, and multiple sclerosis. Moreover, it includes general medicines along with injection devices and disease monitoring software, stressing the importance of comprehensive patient care.

  • Electronics Segment

    Merck KGaA extends its expertise to the semiconductor and display industries by supplying critical materials and solutions for surface design. This encompasses delivery systems and services, as well as innovative surface solutions like cosmetics, effect pigments, and functional solutions. Their contributions are vital for the development and manufacturing processes in the electronics sector, showcasing their versatility and capacity to meet diverse industry needs.

  • In-licensing Agreements and Collaborations

    The company has established several significant in-licensing agreements and collaborations aimed at the development and commercialization of drug candidates. This includes partnerships for targeting conditions like head and neck cancer, metastatic colorectal cancer, and tenosynovial giant cell tumor. Such endeavors signify Merck KGaA's commitment to addressing global health challenges through innovation and strategic partnerships.

Contact Information

Address: Frankfurter Strasse 250
Phone: 49 6151 72 0